Abstract | BACKGROUND: MATERIAL AND METHODS: RESULTS: Forty patients were available for final evaluation. Median age of presentation of patients was fifty-six years. Thirteen patients had Non small cell lung cancer stage IIIA while twenty-seven patients had Stage IIIB disease. Anemia was the most common hematological toxicity observed (seen in 81% of patients). Nausea and vomiting were the most common non-hematological toxicity seen. Sensory neuropathy was seen in 38% of patients. 88% patients developed alopecia. Seven patients developed febrile neutropenias. CONCLUSION: Neo- adjuvant chemotherapy using Cisplatin and Etoposide continues to be a basic regimen in the Indian set up despite availability of higher molecules, since it is cost effective, well tolerated and therapeutically effective. Blood transfusions, growth factors and supportive care can be used effectively to over come toxicity associated with this regimen.
|
Authors | Amit Bahl, D N Sharma, P K Julka, G K Rath |
Journal | Journal of cancer research and therapeutics
(J Cancer Res Ther)
2006 Jan-Mar
Vol. 2
Issue 1
Pg. 14-6
ISSN: 1998-4138 [Electronic] India |
PMID | 17998666
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology, radiotherapy)
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Etoposide
(administration & dosage)
- Female
- Humans
- Lung Neoplasms
(drug therapy, pathology, radiotherapy)
- Male
- Middle Aged
- Neoadjuvant Therapy
(adverse effects)
|